Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

02. Urotelial Cancer (1375) > HYU Onc - Bladder and Upper Tract > Flashcards

HYU Onc - Bladder and Upper Tract Flashcards

1
Q

Microhematuria definition

A

> or = 3 RBCs/hpf on microscopic evaluation of a single, properly collected urine specimen

Evaluation should not change based on presence or absence of AC/anti-plt meds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Microhematuria: Low-Risk

A

Must meet ALL of the following criteria:

Women < 50yo
Men < 40yo
<10 pack-years
3-10 RBCs/hpf
No prior episodes of MF
No other risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Microhematuria: Intermediate Risk

A

If you meet ANY of the following criteria:

Women 50-59 yo
Men 40-59 yo
11-30 pack years
11-25 RBCs/ hpf
Presence of additional risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Microhematuria: High Risk

A

If you meet ANY of the following criteria:

Man or woman >60yo
>30 pack years
>25 RBCs/hpf
History of gross hematuria
Previously low-risk without prior evaluation and >25 RBCs/hpf

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Management of low-risk microhematuria

A

Shared decision making

Can repeat UA within 6 months or
Cysto + US

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Management of intermediate-risk microhematuria

A

Cysto + RUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Management of high-risk microhematuria/gross hematuria

A

Cysto (for all)
CTU > MRU > retrograde pyelograms and noncon axial imaging or RUS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Additional risk factors for urothelial carcinoma

A

Irritative LUT voiding symptoms
History of cyclophosphamide of ifosfamide chemotherapy
Family history of US or lynch syndrome
Occupational exposure to benzene chemicals or aromatic amines
History of chronic indwelling foreign body in the urinary tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Imaging when microhematuria in a patient with family history of RCC or known genetic renal tumor syndrome

A

Perform upper tract imaging regardless of risk stratification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

When use urine cytology and markers in MH patients?

A

Do not use in initial MH evaluation
Can use cytology for patients with persistent MH + irritative LUTS or RFs for CIS after a negative initial MH workup

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MH follow-up after negative evaluation

A

Repeat UA in 12 months

If UA negative, discontinue further evaluation
If UA persistent MH, shared decision making regarding need for initial evaluation

After negative evaluation, initiate further evaluation if new gross hematuria, increasing degree of MH, or new urologic symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Bladder Cancer Staging

A

Tis = mucosa
T1 = lamina propria
T2 = Muscularis propria
- a = inner
- b = outer
T3 = Perivesical tissue/fat
- a = microscopic
- b = macroscopic
T4 = Extravesical
- a = adjacent organs
- b = body wall

Ta: This refers to noninvasive papillary carcinoma. This type of growth often is found on a small section of tissue that easily can be removed with TURBT.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Low risk bladder cancer

A

LG solitary Ta less than or = to 3 cm
PUMLUMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Intermediate Risk Bladder Cancer

A

Recurrence of LG Ta within 1 year
Solitary LG Ta >3cm
Multifocal LG Ta
HG Ta < or = to 3 cm
Any LG T1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

High Risk Bladder Cancer

A

HG T1
Any Recurrent HG Ta
HG Ta > 3 cm or multifocal
Any CIS
Any BCG failure in HG patient
Any variant histology (micropapillary, sarcomatoid, plasmacytoid)
Any LVI
Any HG prostatic urethral involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Positive cytology with normal cysto in a patient with a history of NMIBC

A

Consider upper tract imaging, prostatic urethral biopsies, blue light cysto, ureteroscopy, random bladder biopsies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Variant histology, extensive squamous or glandular differentiation, + LVI

A

Obtain GU pathologist review
Offer restaging TURBT 4-6 weeks after diagnostic TURBT (if attempting to spare bladder)
Or, offer up front radical cystectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

When is the use of urine markers appropriate?

A

For NMIBC, can use biomarkers to assess response to BCG and to adjudicate equivocal cytology
- Should NOT use in lieu of cytology
- Should NOT use for surveillance of low risk patients with with normal cytology
- SHOULD use cytology with surveillance cystoscopy for IR and HR disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

When do you perform a restaging TURBT?

A

Within 6 weeks of initial TURBT

If incomplete resection

If pathology is high-risk HG Ta OR HG T1
Must get muscle in specimen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Single dose intravesical MMC or gemcitabine use?

A

Postop

Consider in suspected/known LG disease within 24 hours of TURBT, except in cases of suspected perforation or extensive resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

When do you use BCG?

A

Don’t use in LR
Consider in IR
Use in HR

If it works, maintenance BCG (3 weekly doses starting 3 months after induction) for 1 year in IR and 3 years in HR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is maintenance BCG dosing/timing?

A

If it works, maintenance BCG (3 weekly doses starting 3 months after induction) for 1 year in IR and 3 years in HR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What do you do for persistent/recurrent NMIBC s/p 1 induction course of BCG?
- Ta?
- CIS?
- HG T1?

A

Ta - Second induction course of BCG
CIS - Second induction course of BCG
RC w/o NAC also an option for both of these

HG T1 - RC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Persistent/recurrent HG or CIS within 6 months of 2 induction courses BCG or induction + maintenance BCG?

A

No more BCG

Unwilling or unfit for RC after 2 courses of BCG with recurrence within 12 months –> clinical trial vs other intravesical therapy (valrubicin, gemcitabine, docetaxel), vs. systemic pembro for CIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Cystoscopy follow-up for bladder cancer patients

A

After initial evaluation/treatment, first surveillance cysto should be within 3-4 months

If this is negative, the frequency of subsequent surveillance cysto (w/ cytology if IR/HR) varies based on risk stratification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Low-risk NMIBC surveillance cysto schedule

A

After initial evaluation/treatment, first surveillance cysto should be within 3-4 months

Next cysto 6-9 months later
Then yearly

Shared decision making after 5 years

*In-office fulguration is an option for LG Ta disease with <1cm papillary recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Intermediate-risk NMIBC surveillance cysto schedule

A

After initial evaluation/treatment, first surveillance cysto should be within 3-4 months

Cysto/cytology q3-6 months x2 years
q6-12 months x2 years
Then yearly

Consider surveillance upper tract imaging every 1-2 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

High-risk NMIBC surveillance cysto schedule

A

After initial evaluation/treatment, first surveillance cysto should be within 3-4 months

Cysto/cytology q3-4 months x2 years
q6 months x2 years
Then yearly

Consider surveillance upper tract imaging every 1-2 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Treatment for BCG sepsis
- MOA for the drugs?

A

Corticosteroids + NSAIDs + Isoniazid 300mg + Rifampin 600mg + Ethambutol 1200mg daily

Isoniazid inhibits mycobacterial cell wall formation
Rifampin inhibits RNA polymerase
Ethambutol inhibits mycobacterial cell wall formation

Pyridoxine (B6) is administered with Isoniazid to prevent peripheral neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Persistent fever without sepsis or UTI following BCG

A

Isoniazid x 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Timing of BCG and TURBT

A

Don’t give BCG until >1 week after TURBT due to risk of BCG sepsis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Can you give BCG in immunocompromised patients?

A

BCG is safe in immunocompromised patients
- Including patients with autoimmune disease, transplant patients, and patients undergoing systemic chemotherapy

BCG is dependent on an intact immune system, so use MMC (DNA x-linker) for intravesical therapy in patients on immunosuppression (chronic steroids for RA or anti-TNFa for Crohn’s)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Urothelial CIS of the prostatic urethra during TURP?

A

Repeat BCG Tx to reduce recurrence of CIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Positive cytology and negative cysto?

A

Prostatic urethral biopsies should include at 5 and 7 o’clock positions, where the ejaculatory ducts insert

These are most common sites of occult disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Granulomatous prostatitis

A

Common following iBCG

No intervention needed
mBCG can continue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Valrubicin uses

A

Valrubicin is FDA approved for BCG-refractory CIS and HR disease in a non-cystectomy candidate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Recurrent tiny (<1cm) low grade Ta after BCG

A

fulgurate and observe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Persistent CIS after induction in a high risk patient

A

Repeat induction BCG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Best method for detecting recurrent CIS after induction BCG

A

blue-light cysto

Hexaminolevulinate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

BCG-unresponsive

A

Persistent/recurrent NMIBC must undergo iBCG + at least one mBCG to be ‘BCG-unresponsive’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Anktiva

A

IL-15 superantagonist - used with BCG in BCG- unresponsive CIS +/- Ta/T1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Side effects of MMC

A

9% rash (contact dermatitis)
6-41% chemical cystitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

How to optimize MMC effectiveness

A

Void/CIC prior
Dehydration to prevent dilution
Alkalinization with Na-bicarb
Increase drug concentration (want 40mg/20mL)

Not helpful: abx, NSAIDs, antimuscarinics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

T1 tumors with aggressive features
(>3 cm, micropapillary/variant histology, concomitant CIS, LVI)

A

Up front cystectomy without NAC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

When do you treat asymptomatic ileal conduit urine cultures?

A

Asymptomatic IC cultures are >75% positive
Only need to be treated if culture grows proteus or pseudomonas due to risk of stone formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Risk of LN metastasis at time of RC performed for recurrent T1 or CIS

A

10-15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Nephroureterectomy in a patient with one kidney and prior RC/IC

A

Leave IC in place for use with future renal transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Persistent disease (any) on mid-cycle TURBT during chemoradiation

A

Proceed to RC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Urine Assay: UroVysion FISH

A

Detects aneuploidy from chromosome 3, 7 and 17 and homozygous loss of chromosome 9p21

Can adjudicate equivocal urine cytology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Urine Assay: ImmunoCyt

A

Immunohistochemistry for urothelial antigens

Can adjudicate equivocal cytology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Urine Assay: BladderCheck

A

Enzyme innunoassay for NMP22

Used with cytology for Dx and surveillance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Urine Assay: BTA

A

Enzyme immunoassay for bladder tumor antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Nephrogenic Adenoma
- What is it?
- Sxs?
- Tx?

A

Rare benign metaplastic response to urothelium injury

Hematuria and irritative voiding sxs

Cystoscopy looks like low-grade papillary tumor

TUR + > or = 1 years of antibiotic suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Inverted papilloma of the ureter

A

Can behave malignantly, so survey bladder and upper tracts

Conservative management with surveillance for at least two years is recommended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Instillation of periop chemo after complete TURBT only works if given within how long?

A

24 hours after surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

5mm filling defect in distal ureter + biopsy shows LG UC

A

Ureteroscopic tumor ablation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Risk of upper tract UC in patient with bladder Ca diagnosis?

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Risk of bladder cancer in patients with UTUC diagnosis?

A

~40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

How to follow cystitis glandularis?

A

Could have risk of transformation to adenocarcinoma
Survey with cysto or UA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Lit: SWOG 8216
1991

A

Intravesical BCG > Doxorubicin for preventing NMIBC recurrence

RCT
BCG = immune system activator
Doxorubicin = DNA intercalator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Lit: BCG Complications
1992

A

Intravesical BCG is generally well tolerated but can lead to serious adverse effects

2.9% fever
0.9% granulomatous prostatitis
0.7% PNA/hepatitis
0.5% arthralgias
1% hematuria
0.3% rash
0.3% ureteral obstruction
0.4% epididymitis
0.2% contracted bladder
0.1% renal abscess
0.4% sepsis
0.1% cytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Management of BCG-related complications?
- Fever >38.5C
- Allergic reaction
- Acute severe illness
- Sepsis

A

Fever >38.5C: Isoniazid 300mg daily for 3 months
- Can resume BCG when asymptomatic

Allergic reaction: Isoniazid 300mg daily for 3 months
- Further BCG if benefits outweigh risks

Acute severe illness: Isoniazid 300mg, rifampin 600mg, ethambutol 1200mg daily for 6 months
- No further BCG

Sepsis: Isoniazid 300mg, rifampin 600mg, ethambutol 1200mg daily for 6 months
- Also consider prednisone 40mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Lit: Post-TURBT MMC
1996

A

Post-TURBT MMC decreases risk of recurrence

RCT
5-year follow-data favored MMC over nothing

64
Q

Lit: SWOG 8507
2000

A

Maintenance BCG doubles RFS compared to induction BCG alone in HR NMIBC

RCT
Similar 5-yr OS

65
Q

Lit: Valrubicin for BCG-refractory CIS
2000

A

FDA-approved for treatment of BCG-refractory CIS in non-cystectomy candidates

Phase III trial

Valrubicin = anthracycline chemo - DNA intercalation

66
Q

Lit: EORTC 30692
2013

A

3 years (vs. 1 year) of mBCG is helpful in HR (but not IR) NMIBC

RCT

67
Q

Lit: SWOG S0337
2018

A

Immediate post-TURBT Gemcitabine reduces recurrence of low-risk NMIBC

RCT
Gemcitabine = DNA synthesis inhibitor

68
Q

Lit: KEYNOTE 057
2021

A

Pembrolizumab is approved for use in BCG-unresponsive NMIBC

Single arm

69
Q

Lit: Nadofaragene Firadenovec for BCG-unresponsive NMIBC
2021

A

CIS unresponsive to BCG may have durable response to nadofaragene

Phase III trial

Nadofaragene = delivers IFN-alpha/2beta cDNA to bladder epithelium and activates immune system

FDA approved in 2022

70
Q

BCG: MOA

A

Immune system activator

71
Q

MMC: MOA

A

Alkylating chemotherapy - DNA cross-linker

72
Q

Valrubicin: MOA

A

Anthracycline chemotherapy - DNA intercalation

73
Q

Gemcitabine: MOA

A

DNA synthesis inhibitor

74
Q

Pembrolizumab: MOA

A

IgG4-mAb to PD-1
Decreases T-cell suppression
Increases T-cells killing cancer cells

This is IV/systemic

75
Q

Nadofaragene: MOA

A

Delivers IFN alpha/2beta to bladder epithelium
Activates immune system

76
Q

BCG Shortage recommendations: 2020

A

Don’t use BCG in LR disease

For IR disease, use intravesical chemo (MMC, gemcitabine, epirubicin, docetaxel)

Use the available BCG for HR NMIBC induction
- If needed, BCG dose can be reduced to 1/2 or 1/3rd strength

If enough BCG is available to offer mBCG - reduce to 1/3rd strength and limit to one year of maintenance

If BCG shortage –> prioritize iBCG for HR over mBCG

If BCG is unavailable –> MMC is the preferred alternative

77
Q

Newly diagnosed CIS and BCG is unavailable

A

MMC

78
Q

HR bladder cancer patients with HR features (HGT1 + CIS, LVI, PUI, variant histology) who are surgical candidates and who are unwilling to take any oncologic risk by using a non-BCG regimen

A

Offer radical cystectomy

79
Q

Workup for patients with suspected UTUC

A

Cystoscopy
Cross-sectional imaging of upper tracts with contrast and with delays

Also, diagnostic URS with washings and biopsy of any concerning lesions identified

80
Q

If bladder and upper tract tumors discovered during evaluation of upper tracts?

A

Deal with bladder lesions in same sitting as upper tract eval

81
Q

If upper tract is difficult to access due to stricture?

A

Minimize risk of ureteral injury by using gentle dilation techniques such as ureteral stenting

Don’t use a sheath or try to dilate

82
Q

In cases where ureteroscopy cannot be safely performed or is not possible, but UTUC is suspected?

A

An attempt at selective upper tract
washing or barbotage for cytology may be made and pyeloureterography performed in cases where good quality imaging such as CT or MR urography cannot be obtained

83
Q

Should you inspect both sides when one UT is concerning for cancer? Or only one?

A

At the time of ureteroscopy for suspected UTUC, clinicians should not perform ureteroscopic inspection of a radiographically and clinically normal contralateral upper tract.

84
Q

For patients with suspected/diagnosed UTUC, when do you send them to genetic counseling?

A

If they have a personal or family history of Lynch Syndrome

(colorectal, ovarian, endometrial, gastric, biliary, small bowel, pancreatic, prostate, skin and brain cancer)

85
Q

Favorable low-risk UTUC features

A

Biopsy Low-grade
Negative cytology
No invasion
No obstruction
Normal nodes
Unifocial, papillary in appearance
No lower tract involvement

Treatment: Ablation preferred, no systemic therapy

86
Q

Unfavorable Low-Risk UTUC features

A

Biopsy Low-grade
No HGUC on cytology
No invasion
Can have obstruction
Normal Nodes
Multifocal
Papillary appearance
Can have bladder involvement

Ablative therapy can be offered, No systemic therapy

87
Q

Favorable High-Risk UTUC features

A

Biopsy high-grade
Any cytology
No invasion
No obstruction
Normal nodes
Unifocal
Papillary appearance
No lower tract involvement

Ablative therapy in rare, selected cases
Recommend neoadjuvant or adjuvant systemic therapy

88
Q

Unfavorable High-Risk UTUC features

A

Biopsy high-grade
HGUC on cytology
Invasion
Obstruction
Suspicious nodes
Multifocal
Sessile or Flat lesions
Lower tract involvement

Ablation for palliation
Recommend neoadjuvant or adjuvant systemic therapy

89
Q

Initial management option for patients with LR favorable UTUC

A

Tumor ablation

90
Q

Initial management option offered to patients with LR unfavorable UTUC and select patients with HR favorable disease who have low-volume tumors or who cannot undergo Radical Nephroureterectomy

A

Tumor ablation

91
Q

Tumor ablation - retrograde or antegrade? Next endo eval?

A

Tumor ablation may be accomplished via a retrograde or antegrade percutaneous approach and repeat endoscopic evaluation should be performed within three months

92
Q

Role of intravesical or pelvicalycel chemo in UTUC ablation?

A

Following ablation of UTUC tumors and after confirming there is no perforation of the bladder or upper tract, clinicians may instill adjuvant pelvicalyceal chemotherapy (Conditional Recommendation; Evidence Level: Grade
C) or intravesical chemotherapy (Expert Opinion) to decrease the risk of urothelial cancer recurrence.

93
Q

Pelvicalyceal therapy with BCG may be offered to patients with HR favorable UTUC after complete tumor ablation or patients with upper tract carcinoma in situ (CIS)

A

Pelvicalyceal therapy with BCG may be offered to patients with HR favorable UTUC after complete tumor ablation or patients with upper tract carcinoma in situ (CIS)

94
Q

When do you perform NephU in LR UTUC?

A

When tumor ablation is not feasible or evidence of risk group progression is identified in patients with LR UTUC,
surgical resection of all involved sites either by RNU or segmental resection of the ureter should be offered

95
Q

Choice therapy for patients with HR UTUC?

A

Clinicians should recommend RNU or segmental ureterectomy for surgically eligible patients with HR UTUC.

Make sure to also give a single dose of chemo intravesically

96
Q

Best treatment option for surgically eligible patients with HR and unfavorable LR UTUC cancers endoscopically confirmed as confined to the lower ureter in a functional renal unit

A

Distal ureterectomy and ureteral reimplantation is the preferred treatment

Make sure to also give a single dose of chemo intravesically

When performing NU or distal ureterectomy, the entire distal ureter including the intramural ureteral tunnel and ureteral orifice should be excised, and the urinary tract should be closed in a watertight fashion

97
Q

LND in UTUC surgery?

A

For patients with LOW RISK UTUC, clinicians MAY perform LND at time of NU or ureterectomy

For patients with HIGH RISK UTUC, clinicians SHOULD perform LND at time of NU or ureterectomy

98
Q

When to consider neoadjuvant chemo in UTUC management?

A

Clinicians should offer cisplatin-based NAC to patients undergoing RNU or ureterectomy with HR UTUC, particularly in those patients whose post-operative eGFR is expected to be less than 60 or those with other
medical comorbidities that would preclude platinum-based chemotherapy in the post-operative setting

99
Q

When to us adjuvant chemo in UTUC management?

A

Clinicians should offer platinum-based adjuvant chemotherapy to patients with advanced pathological stage (pT2–T4 pN0–N3 M0 or pTany N1–3 M0) UTUC after RNU or ureterectomy who have not received neoadjuvant platinum based therapy

Adjuvant nivolumab therapy may be offered to patients who received neoadjuvant platinum-based chemotherapy (ypT2–T4 or ypN+) or who are ineligible for or refuse perioperative cisplatin (pT3, pT4a, or pN+).

100
Q

Metastatic UTUC patients treatment?

A

In patients with metastatic (M+) UTUC, RNU or ureterectomy should not be offered as initial therapy

Patients with clinical, regional node-positive (cN1-3, M0) UTUC should initially be treated with systemic therapy. Consolidative RNU or ureterectomy with lymph-node dissection may be performed in those with a partial or complete response

101
Q

Upper tract CIS with low tolerance for nephrol loss (eg CKD, history of stones)

A

PCN with antegrade BCG instillation is more effective than ureteral stent placement and bladder instillation

102
Q

Upper tract UC before age 55

A

Genetic counseling if positive for lynch syndrome (HNPCC)

103
Q

Balkan Nephropathy

A

Long-term consumption of aristolochic acid increases the risk of UTUC and ESRD

104
Q

Lit: (don’t) POUT (it worked)
Peri-operative chemotherapy vs. surveillance in Upper Tract UC
2020

A

Adjuvant systemic gem/cis improves DFS over placebo after NUx for advanced, non-metastatic UTUC

This was surveillance vs. adjuvant gem/cis

RCT

105
Q

Lit: OLYMPUS
2022

A

MMC gel injected into upper tract weekly works to destroy low-grade UTUC but is associated with ureteral stenosis in almost 50% of patients

Phase III
6 weekly instillations of Jelmyto - retrograde

Complete responders eligible for monthly maintenance instillation

106
Q

Need to stage non-metastatic muscle invasive bladder cancer prior to recommending treatment. How?

A

CT Urogram
CBC
CMP
Chest imaging
Bone imaging if clinical suspicion (increased ALP) or symptoms of bone mets

107
Q

Role of NAC and AC in MIBC (non-metastatic)

A

Generally, patients should get cisplatin-based NAC followed by RC within 12 weeks of NAC

Neoadjuvant carboplatin-based chemo should NOT be used (if cisplatin ineligible –> up front RC vs. clinical trial)

Cisplatin-based adjuvant chemo if non-organ confined disease at cystectomy (T3, T4 or N+)

108
Q

Cystectomy for M0 disease

A

Do bilateral pelvic lymph node dissection (BPLND) (at least external/internal iliac and obturator nodes)

Remove bladder, prostate, SVs in med
Remove bladder +/- adjacent organs in women

Consider sexual function preserving procedures depending on extent of disease

When creating a neobladder, verify a negative urethral margin first

109
Q

Medications to use in cystectomy periop period

A

mu-opioid antagonists (alvimopan) unless contraindicated

Pharmacologic VTE prophylaxis should be used

110
Q

Bladder preservation in non-metastatic MIBC

A

Maximal TURBT
Radiosensitization (cisplatin of 5-FU/MMC)
EBRT
Surveillance cysto

RC for MIBC recurrence

TURBT or RC for NMIBC recurrence

Radiation monotherapy should not be offered

111
Q

Follow-up for non-metastatic muscle invasive bladder cancer

A

Chest imaging
Cross-sectional AP imaging q6-12 months x 3 years and then annually
Labe q3-6 months for 3 years and then annually

Monitor urethral remnant if present

112
Q

MIBC, chemo type, and timing

A

Most patients with MIBC should get cisplatin-based NAC prior to RC

113
Q

Contraindications to cisplatin-based chemotherapy

A

Poor performance status
CrCl <60
Significant hearing loss
Significant peripheral neuropathy
NYHA Class 3+ HF

114
Q

Muscle invasive small cell carcinoma treatment

A

Muscle invasive small cell carcinoma responds well to cisplatin based neoadjuvant chemo followed by surgery OR radiation
(Cure rate 40-60% vs. 5-20% without NAC)

Cisplatin + ETOPOSIDE (not gemcitabine) is the standard regimen

115
Q

Treatment for pure variant histology (micropapillary, squamous, adenocarcinoma (colonoscopy required in workup), plasmacytoid, and sarcomatoid) tumors

A

Pure variant histology tumors should generally be treated with upfront cystectomy (no NAC)

116
Q

MIBC in conjunction with variant histology should (generally) be managed how?

A

NAC prior to local treatment

117
Q

Neoadjuvant chemo and NON-MIBC?

A

NAC has NOT been found to be of benefit in patient undergoing RC for non-muscle invasive disease

118
Q

Major metabolic anomaly with ileum or colon diversion

A

HYPERchloremic metabolic acidosis
- Due to absorption of ammonium ions (absorbed with Cl-) in exchange for carbonic acid and water (secreted)

119
Q

Major metabolic anomaly with ileum or colon diversion - treatment?

A

Treat with:
1. Decreased transit time (CIC)
2. Alkalinizing agents (bicrab, citrate)
3. Inhibitors of Cl- transport (chlorpromazine, nicotinic acid)

120
Q

Ureterosigmoid (colon) vs. ileal conduit
- Metabolic derangements?
- Risks?

A

Both create a hyperchloremic metabolic acidosis

  • Risk of colon cancer with colon conduit
  • Risk of worse (more frequent and more severe) metabolic derangements with colon

Osteomalacia is most likely with colonic continent diversions
- MAc gets buffered by bone with release of Ca++
- Mineralized bone is reduced and osteoid component becomes excessive
- Lethargy, joint pain, proximal myopathy, elevated alk phos
– Treat by correcting acidosis with K-cit and Ca++ supplementation

121
Q

Major metabolic abnormality seen after RC/IC

A

HYPER-Cl
HYPO-K
Metabolic acidosis

122
Q

Jejunal conduit metabolic derangement

A

Also ACIDOSIS
But with opposite electrolyte derangements

So, HYPO-Cl and HYPER-K

Treat by rehydrating and alkalinizing (PO hydration, NaCl and bicarb (NaHCO3))

123
Q

Stomach conduit metabolic derangement and treatment

A

Stomach conduit abnormalities are like vomiting

Metabolic alkalosis (lose your stomach acid)
HYPO-Cl
HYPO-K

Tx:
Rehydration with NS
KCl replacement
H2 blockers
PPI

124
Q

How does B12 deficiency present? When does it happenin Urology/bladder Ca?

A

B12 deficiency presents with anemia and neurologic abnormalities (numbness and postural hypotension)

Nutritional problems (B12 deficiency and bile acid salt absorption) are less with colon when compared to ileum as long as ileocecal valve is left intact

B12 is a coenzyme in the metabolism of homocysteine
- Homocysteine will build up in serum in absence of adequate B12

125
Q

Ileal conduit and ‘water under the bridge’

A

IC should be formed “under” (inferior to) the bowel anastomosis

126
Q

Most accurate way to assess renal function s/p ileal conduit

A

FeNa

127
Q

Next step: decreased UOP and increased drain output 4 days after RC/IC

A

Place a catheter in stoma

128
Q

Urinary ammonium excreted by the kidneys (collecting duct) is absorbed by intestinal conduit…

What can happen next?
Treatment?
If symptoms are relatively mild?

A

The liver metabolizes the ammonia to urea (via ornithine cycle)

If liver function is decreased, can lead to increased ammonia buildup and you can go into ammoniagenic coma

Treat with oral neomycin or lactulose to reduce absorption in GI tract

*If sxs are milder (lethargy with increased transaminases), start with continuous drainage of urinary diversion

129
Q

Necrotic looking stoma. Next step?

A

Loop endoscopy with or without diagnostic lap to determine extent of ischemic segment prior to operative intervention

If just very distal conduit is involved, can consider stoma revision alone without resection of the entire conduit

130
Q

Next step?: Enteral-conduit fistula –> feculent urine

A

Start with catheter in conduit + low residue diet

Surgical intervention PRN

131
Q

Largest risk factor for parastomal hernia

A

Stoma placement lateral to the rectus abdominus

132
Q

Next step?: Pyocystis s/p ileal conduit w/o cystectomy

A

First line treatment is bladder irrigations

If persistent problems like sepsis, vesicovaginostomy formation improves symptoms without morbidity of cystectomy

133
Q

Bowel prep needed for small bowel diversion?

A

No, mechanical bowel prep is NOT indicated for most patients having a diversion with small bowel

134
Q

Next step: Calculus in ileal conduit?

A

Most will pass spontaneously
- Initial observation is preferred in an asymptomatic patient in absence of hydronephrosis or other evidence of conduit obstruction

135
Q

Next step?: Suspicious or positive urethral wash s/p RC/IC for BCG-refractory CIS

A

Staging imaging

Urethrectomy if imaging negative

136
Q

Next step?: New hydronephrosis in patient with RC/IC

A

Loopogram to determine presence/absence of reflux

If no reflux, get lasix renogram to determine level of obstruction
- Consider CTU to evaluate for extrinsic vs. intrinsic mass at site of obstruction prior to nephrostomy tube placement

+/- nephrostomy tube

Endoscopic +/- laparoscopic management

137
Q

Ureteroenteric anastomotic strictures: Work-Up?

A

First rule out malignant cause of stricture (ureteroscopy +/- biopsy +/- cytology)

The assess kidney function (renogram)

Then consider length of strictures
- If <2cm could try endoscopic procedure
If > 2cm, open repair is best

138
Q

Causes of early vs. late ureteroenteric anastomotic strictures?

A

Early = <1 year after surgery
- Usually due to devascularization of the distal ureter or extreme angulation of the left ureter at the IMA (more common on left side)

Late = usually a fibrotic response at the UE junction

139
Q

Open or endoscopic repair for:
early UEA strictures?
Late UEA strictures?
Long?
Short?

A

Short - can be managed endoscopically in first year or so after surgery

Open surgical repair most effective

Open repair typically needed for longer (>2 cm) or strictures that occur >1 yr after surgery

140
Q

What do you do for obstructed, nonfunctional kidney after RC/IC?

A

NephU should be considered because these units cannot be surveyed for upper tract recurrence using cytology

141
Q

Diarrhea after >40cm but <100cm of ileal resection and RC/IC?

A

Due to decreased ileal bile salt absorption, so there is increased bile salt delivery to the colon

Colonic irritation and increased bicarb and water secretion (secretory diarrhea)

Treat with cholestyramine (bile-acid sequestrant in the GI tract) and decreased fat intake

142
Q

Diarrhea after ileocecal valve or colon resection?

A

Decreased bowel transit time + osmotic diarrhea

Treat with oral bulking agents and loperamide

143
Q

Contraindications for orthotopic ileal neobladder

A

Inability/unwillingness to catheterize
Urethral stricture disease
SUI
GFR <50
Severe liver disease
Positive urethral margin
IBD (crohn’s)
Short bowel syndrome

144
Q

Maneuvers to do if there is difficulty reaching the urethral stump with neobladder

A

Reduce Trendelenburg
Incise peritoneum over the neobladder mesentery
Staple the medial/proximal mesentery while avoiding ischemia
Release ileum around ileocecal junction
Convert to ileal conduit or sigmoid neobladder

145
Q

Abdominal pain over continent diversion and explosive urinary leakage

A

Pouchitis
Urine culture and empiric abx

First line treatment is regular pouch irrigation

Second line is prophylactic abx or urine acidification

146
Q

Why?: Isolated nocturnal incontinence s/p RC/NB

A

Associated with loss of afferent input from the detrusor to CNS, which normally causes a reflex rise in urethral pressure during reservoir filling

147
Q

What is bowel segment of choice in neobladder? Why?

A

Detubularized ileum
Superior compliance
Lowest likelihood of generating intermittent high-pressure contractions

148
Q

Next step?: Urethral recurrence in neobladder

A

If invasive disease –> urethrectomy + urinary diversion

If superficial, can try to TUR or do intraurethral BCG

149
Q

Urethral recurrence after Studer (U-shaped) NB?

A

Urethrectomy + conversion of afferent limb into ileal conduit

150
Q

Omentum blood supply

A

Right gastroepiploic artery

151
Q

First branch off of the internal iliac

A

Umbilical artery
- This gives off the superior vesical arteries before becoming the obliterated umbilical artery (medial umbilical ligament)

Ureter passes medial to the medial umbilical ligament to reach the bladder

Vas deferens enters the pelvis lateral to the epigastrics and then passes medially, anterior to the ureter, to reach the base of the prostate

152
Q

Branches of the External Iliac Artery

A

Inferior epigastric

Deep circumflex iliac

Femoral (gives rise to superficial and inferior external pudendal arteries, which supply blood to rhe penile and lateral scrotal skin, respectively)

153
Q

Posterior branches of the Internal Iliac Artery

A

Iliolumbar, lateral sacral, superior gluteal

Ligation of the internal iliac should only be done distal to the posterior branch to avoid devascularization

154
Q

Anterior branches of the Internal Iliac Artery

A

Umbilical
Obturator
Inferior Gluteal
Uterine (F)
Vaginal (F)
Inferior vesical (blood supply to prostate via prostatic and capsular branches)
Middle Rectal
Superior Vesical (blood supply to vas deferens via vesiculodeferential)
Internal pudendal

155
Q

Celiac Artery Branches

A

Left Gastric artery
Common Hepatic artery
Splenic artery

156
Q

Microhematuria: Intermediate Risk

A

If you meet ANY of the following criteria:

Women 50-59 yo
Men 40-59 yo
11-30 pack years
11-25 RBCs/ hpf
Presence of additional risk factors
Previously low-risk without prior evaluation and 3-25 RBCs/hpf

02. Urotelial Cancer (1375) (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions